E. Kick

发表

Beneficial and Adverse Effects of an LXR Agonist on Human Lipid and Lipoprotein Metabolism and Circulating Neutrophils.

K. Behnia, Rongan Zhang, P. Sleph, 2016, Cell Metabolism.

Pharmacological Characterization of a Novel Liver X Receptor Agonist with Partial LXRα Activity and a Favorable Window in Nonhuman Primates

P. Sleph, T. Kirchgessner, Richard J Martin, 2015, The Journal of Pharmacology and Experimental Therapeutics.

Triazolopyrimidines identified as reversible myeloperoxidase inhibitors.

P. Sleph, L. Abell, D. Gordon, 2017 .

Potent Triazolopyridine Myeloperoxidase Inhibitors.

P. Sleph, S. Jusuf, L. Abell, 2018, ACS medicinal chemistry letters.

Selective FPR2 Agonism Promotes a Proresolution Macrophage Phenotype and Improves Cardiac Structure-Function Post Myocardial Infarction

Rongan Zhang, M. Bouvier, D. Gordon, 2021, JACC. Basic to translational science.

Discovery of BMS-986235/LAR-1219: A Potent Formyl Peptide Receptor 2 (FPR2) Selective Agonist for the Prevention of Heart Failure.

Y. Saito, D. Gordon, R. Wexler, 2020, Journal of medicinal chemistry.

Molecular Mechanisms of Desensitization Underlying the Differential Effects of Formyl Peptide Receptor 2 Agonists on Cardiac Structure-Function Post Myocardial Infarction.

Rongan Zhang, M. Bouvier, C. Sum, 2022, ACS pharmacology & translational science.

Small Molecule and Macrocyclic Pyrazole Derived Inhibitors of Myeloperoxidase (MPO).

S. Jusuf, R. Wexler, J. Smallheer, 2021, Bioorganic & medicinal chemistry letters.

Triazolopyrimidines identified as reversible myeloperoxidase inhibitors.

P. Sleph, L. Abell, D. Gordon, 2017, MedChemComm.

Structure-based design and combinatorial chemistry yield low nanomolar inhibitors of cathepsin D.

I D Kuntz, A G Skillman, T J Ewing, 1997, Chemistry & biology.

Discovery and structure activity relationships of 7-benzyl triazolopyridines as stable, selective, and reversible inhibitors of myeloperoxidase.

Steven A. Spronk, S. Jusuf, L. Abell, 2020, Bioorganic & medicinal chemistry.

Identification of novel functional inhibitors of 17β‐hydroxysteroid dehydrogenase type III (17β‐HSD3)

I. Takenaka, B. Fink, M. Salvati, 2005 .

Expedient method for the solid-phase synthesis of aspartic acid protease inhibitors directed toward the generation of libraries.

J. Ellman, E. Kick, J A Ellman, 1995, Journal of medicinal chemistry.

Preservation of Post-Infarction Cardiac Structure and Function via Long-Term Oral Formyl Peptide Receptor Agonist Treatment

M. Bouvier, D. Gordon, F. Villarreal, 2019, JACC. Basic to translational science.

Identification of novel functional inhibitors of 17beta-hydroxysteroid dehydrogenase type III (17beta-HSD3).

I. Takenaka, B. Fink, M. Salvati, 2005, The Prostate.

Nuclear Hormone Receptor Medicinal Chemistry

P. Cheng, E. Kick, R. Mukherjee, 2010, Burger's Medicinal Chemistry and Drug Discovery.

Plasma biomarkers associated with adverse outcomes in patients with calcific aortic stenosis

Jason W. Moore, M. Hyman, J. Maranville, 2021, European journal of heart failure.

Discovery of Highly Potent Liver X Receptor β Agonists

A. D. Rodrigues, P. Sleph, T. Kirchgessner, 2016, ACS medicinal chemistry letters.

Liver X receptor (LXR) partial agonists: biaryl pyrazoles and imidazoles displaying a preference for LXRβ.

T. Kirchgessner, M. Nanao, I. Schulman, 2015, Bioorganic & medicinal chemistry letters.

Enzymatic resolution of methyl (1RS)-N-tBoc-6-hydroxy-3,4-dihydro-1H-isoquinoline-1-carboxylate by Seaprose S

Ramesh N. Patel, E. Kick, Wu Yang, 2007 .

Beneficial and Adverse Effects of an LXR Agonist on Human Lipid and Lipoprotein Metabolism and Circulating Neutrophils.

Rongan Zhang, P. Sleph, T. Kirchgessner, 2016, Cell metabolism.